Growth/differentiation factor-15: Prostate cancer suppressor or promoter

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 4, 2012, Pages 320-328

  Vahara, P ^a   Hampl, A ^a,b   Kozubik A ^a,c   Soucek K ^b,c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

growth differentiation factor 15; macrophage inhibitory cytokine 1; transforming growth factor

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; GROWTH DIFFERENTIATION FACTOR 15; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE B; PROTEIN P53; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SULINDAC; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BONE METASTASIS; CANCER GROWTH; CD4+ CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CYTOKINE PRODUCTION; DNA SEQUENCE; ENZYME PHOSPHORYLATION; EXON; GENE EXPRESSION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNE RESPONSE; OSTEOCLAST; PAIN; PHENOTYPE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE REGENERATION; TISSUE REPAIR; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

BONE NEOPLASMS; CELL DIFFERENTIATION; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; IMMUNOSUPPRESSION; MALE; MOLECULAR TARGETED THERAPY; OSTEOCLASTS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84869224616     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.6     Document Type: Review

References (111)

1. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11-22. (Pubitemid 38111131)
2. Yang L, Moses HL. Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res 2008; 68: 9107-9111.
3. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 1997; 94: 11514-11519. (Pubitemid 27451030)
4. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 2006; 66: 4983-4986. (Pubitemid 43852864)
5. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59: 901-908. (Pubitemid 32274020)
6. Fairlie WD, Moore AG, Bauskin AR, Russell PK, Zhang HP, Breit SN. MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leukoc Biol 1999; 65: 2-5. (Pubitemid 29024911)
7. Hromas R, Hufford M, Sutton J, Xu D, Li Y, Lu L. PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1997; 1354: 40-44. (Pubitemid 27479891)
8. Yokoyama-Kobayashi M, Saeki M, Sekine S, Kato S. Human cDNA encoding a novel TGF-beta superfamily protein highly expressed in placenta. J Biochem 1997; 122: 622-626. (Pubitemid 27443241)
9. Bottner M, Laaff M, Schechinger B, Rappold G, Unsicker K, Suter-Crazzolara C. Characterization of the rat, mouse, and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1). Gene 1999; 237: 105-111. (Pubitemid 29406202)
10. Brown DA, Bauskin AR, Fairlie WD, Smith MD, Liu T, Xu N et al. Antibody-based approach to high-volume genotyping for MIC-1 polymorphism. Biotechniques 2002; 33: 118-120, 122, 124 passim.
11. Hayes VM, Severi G, Southey MC, Padilla EJ, English DR, Hopper JL et al. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival. Cancer Epidemiol Biomarkers Prev 2006; 15: 1223-1225.
12. Lindmark F, Zheng SL, Wiklund F, Bensen J, Balter KA, Chang B et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004; 96: 1248-1254. (Pubitemid 39232716)
13. Bauskin AR, Zhang HP, Fairlie WD, He XY, Russell PK, Moore AG et al. The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-beta superfamily member, acts as a quality control determinant for correctly folded MIC-1. EMBO J 2000; 19: 2212-2220. (Pubitemid 30259002)
14. Brunner AM, Lioubin MN, Marquardt H, Malacko AR, Wang WC, Shapiro RA et al. Site-directed mutagenesis of glycosylation sites in the transforming growth factor-beta 1 (TGF beta 1) and TGF beta 2 (414) precursors and of cysteine residues within mature TGF beta 1: effects on secretion and bioactivity. Mol Endocrinol 1992; 6: 1691-1700.
15. Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, Hunter M et al. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res 2005; 65: 2330-2336. (Pubitemid 40490143)
16. Abd El-Aziz SH, Endo Y, Miyamaori H, Takino T, Sato H. Cleavage of growth differentiation factor 15 (GDF15) by membrane type 1-matrix metalloproteinase abrogates GDF15-mediated suppression of tumor cell growth. Cancer Sci 2007; 98: 1330-1335. (Pubitemid 47241753)
17. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010; 122: 1387-1395.
18. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E. Growthdifferentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo study. Circulation 2011; 123: 2101-2110.
19. Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 2007; 53: 284-291. (Pubitemid 46338273)
20. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1054-1060. (Pubitemid 47348231)
21. Kempf T, Wollert KC. Growth-differentiation factor-15 in heart failure. Heart Fail Clin 2009; 5: 537-547.
22. Wang F, Guo Y, Yu H, Zheng L, Mi L, Gao W. Growth differentiation factor 15 in different stages of heart failure: potential screening implications. Biomarkers 2010; 15: 671-676.
23. Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F, Wu L et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 2010; 9: 1057-1064.
24. Dinh W, Futh R, Lankisch M, Hess G, Zdunek D, Scheffold T et al. Growthdifferentiation factor-15: a novel biomarker in patients with diastolic dysfunction? Arq Bras Cardiol 2011; 97: 65-75.
25. Stahrenberg R, Edelmann F, Mende M, Kockskamper A, Dungen HD, Luers C et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 2010; 12: 1309-1316.
26. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011; 17: 581-588.
27. de Jager SC, Bermudez B, Bot I, Koenen RR, Bot M, Kavelaars A et al. Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. J Exp Med 2011; 208: 217-225.
28. Song H, Yin D, Liu Z. GDF-15 promotes angiogenesis through modulating p53/HIF-1a signaling pathway in hypoxic human umbilical vein endothelial cells. Mol Biol Rep 2011; e-pub ahead of print 20 July 2011.
29. Brown DA, Moore J, Johnen H, Smeets TJ, Bauskin AR, Kuffner T et al. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum 2007; 56: 753-764. (Pubitemid 46399422)
30. Tamary H, Shalev H, Perez-Avraham G, Zoldan M, Levi I, Swinkels DW et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 2008; 112: 5241-5244.
31. Theurl I, Finkenstedt A, Schroll A, Nairz M, Sonnweber T, Bellmann-Weiler R et al. Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol 2009; 148: 449-455.
32. Dostalova I, Roubicek T, Bartlova M, Mraz M, Lacinova Z, Haluzikova D et al. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol 2009; 161: 397-404.
33. Sugulle M, Dechend R, Herse F, Weedon-Fekjaer MS, Johnsen GM, Brosnihan KB et al. Circulating and placental growth-differentiation factor 15 in preeclampsia and in pregnancy complicated by diabetes mellitus. Hypertension 2009; 54: 106-112.
34. Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol 2011; 17: 184-190.
35. Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, Koniaris LG. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 2005; 23: 543-548. (Pubitemid 40677428)
36. Duong Van Huyen JP, Cheval L, Bloch-Faure M, Belair MF, Heudes D, Bruneval P et al. GDF15 triggers homeostatic proliferation of acid-secreting collecting duct cells. J Am Soc Nephrol 2008; 19: 1965-1974.
37. Strelau J, Strzelczyk A, Rusu P, Bendner G, Wiese S, Diella F et al. Progressive postnatal motoneuron loss in mice lacking GDF-15. J Neurosci 2009; 29: 13640-13648.
38. Schindowski K, von Bohlen und Halbach O, Strelau J, Ridder DA, Herrmann O, Schober A et al. Regulation of GDF-15, a distant TGF-beta superfamily member, in a mouse model of cerebral ischemia. Cell Tissue Res 2011; 343: 399-409.
39. Marjono AB, Brown DA, Horton KE, Wallace EM, Breit SN, Manuelpillai U. Macrophage inhibitory cytokine-1 in gestational tissues and maternal serum in normal and pre-eclamptic pregnancy. Placenta 2003; 24: 100-106. (Pubitemid 37184701)
40. Tong S, Marjono B, Brown DA, Mulvey S, Breit SN, Manuelpillai U et al. Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. Lancet 2004; 363: 129-130. (Pubitemid 38068331)
41. Wallace EM, Marjono B, Brown DA, Crossley J, Tong S, Aitken D et al. Maternal serum and amniotic fluid levels of macrophage inhibitory cytokine 1 in Down syndrome and chromosomally normal pregnancies. Prenat Diagn 2004; 24: 224-226. (Pubitemid 38428865)
42. Soucek K, Slabakova E, Ovesna P, Malenovska A, Kozubik A, Hampl A. Growth/ differentiation factor-15 is an abundant cytokine in human seminal plasma. Hum Reprod 2010; 25: 2962-2971.
43. Dostalova I, Kavalkova P, Papezova H, Domluvilova D, Zikan V, Haluzik M. Association of macrophage inhibitory cytokine-1 with nutritional status, body composition and bone mineral density in patients with anorexia nervosa: the influence of partial realimentation. Nutr Metab (Lond) 2010; 7: 34.
44. Jatoi A. Weight loss in patients with advanced cancer: effects, causes, and potential management. Curr Opin Support Palliat Care 2008; 2: 45-48.
45. Vila G, Riedl M, Anderwald C, Resl M, Handisurya A, Clodi M et al. The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clin Chem 2011; 57: 309-316.
46. Wakchoure S, Swain TM, Hentunen TA, Bauskin AR, Brown DA, Breit SN et al. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Prostate 2009; 69: 652-661.
47. Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 2007; 13: 1333-1340. (Pubitemid 350073601)
48. Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P et al. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 2009; 150: 1688-1696.
49. Kim JH, Kim KY, Jeon JH, Lee SH, Hwang JE, Lee JH et al. Adipocyte culture medium stimulates production of macrophage inhibitory cytokine 1 in MDA-MB-231 cells. Cancer Lett 2008; 261: 253-262.
50. Bock AJ, Stavnes HT, Kempf T, Trope CG, Berner A, Davidson B et al. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. Int J Gynecol Cancer 2010; 20: 1448-1455.
51. Wong J, Li PX, Klamut HJ. A novel p53 transcriptional repressor element (p53TRE) and the asymmetrical contribution of two p53 binding sites modulate the response of the placental transforming growth factor-beta promoter to p53. J Biol Chem 2002; 277: 26699-26707. (Pubitemid 34967169)
52. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005; 67: 356-364. (Pubitemid 40216727)
53. Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther 2003; 2: 1023-1029.
54. Baek SJ, Wilson LC, Lee CH, Eling TE. Dual function of nonsteroidal antiinflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002; 301: 1126-1131. (Pubitemid 34595106)
55. Lee SH, Krisanapun C, Baek SJ. NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta, C/EBPbeta and ATF3. Carcinogenesis 2010; 31: 719-728.
56. Yoshioka H, Kamitani H, Watanabe T, Eling TE. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A. J Biol Chem 2008; 283: 33129-33137.
57. Lincova E, Hampl A, Pernicova Z, Starsichova A, Krcmar P, Machala M et al. Multiple defects in negative regulation of the PKB/Akt pathway sensitise human cancer cells to the antiproliferative effect of non-steroidal anti-inflammatory drugs. Biochem Pharmacol 2009; 78: 561-572.
58. Zimmers TA, Gutierrez JC, Koniaris LG. Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer. J Cancer Res Clin Oncol 2010; 136: 571-576.
59. Kim KS, Rhee KH, Yoon JH, Lee JG, Lee JH, Yoo JB. Ginkgo biloba extract (EGb 761) induces apoptosis by the activation of caspase-3 in oral cavity cancer cells. Oral Oncol 2005; 41: 383-389. (Pubitemid 40387867)
60. Kim JS, Baek SJ, Sali T, Eling TE. The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther 2005; 4: 487-493. (Pubitemid 40443934)
61. Bottone Jr FG, Baek SJ, Nixon JB, Eling TE. Diallyl disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J Nutr 2002; 132: 773-778. (Pubitemid 34275081)
62. Kelly JA, Lucia MS, Lambert Jr. p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms. Cancer Lett 2009; 277: 38-47.
63. Auyeung KK, Cho CH, Ko JK. A novel anticancer effect of astragalus saponins: Transcriptional activation of NSAID-activated gene. Int J Cancer 2009; 125: 1082-1091.
64. Schlittenhardt D, Schober A, Strelau J, Bonaterra GA, Schmiedt W, Unsicker K et al. Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res 2004; 318: 325-333. (Pubitemid 39506502)
65. Baek KE, Yoon SR, Kim JT, Kim KS, Kang SH, Yang Y et al. Upregulation and secretion of macrophage inhibitory cytokine-1 (MIC-1) in gastric cancers. Clin Chim Acta 2009; 401: 128-133.
66. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008; 1: 13.
67. Wollmann W, Goodman ML, Bhat-Nakshatri P, Kishimoto H, Goulet Jr RJ, Mehrotra S et al. The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. Carcinogenesis 2005; 26: 900-907. (Pubitemid 41214318)
68. Kim KK, Lee JJ, Yang Y, You KH, Lee JH. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 2008; 29: 704-712. (Pubitemid 351494157)
69. Burris 3rd HA. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004; 9 (Suppl 3): 10-15.
70. Si Y, Liu X, Cheng M, Wang M, Gong Q, Yang Y et al. Growth differentiation factor 15 is induced by hepatitis C virus infection and regulates hepatocellular carcinoma-related genes. PLoS One 2011; 6: e19967.
71. Boyle GM, Pedley J, Martyn AC, Banducci KJ, Strutton GM, Brown DA et al. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol 2009; 129: 383-391.
72. Huh SJ, Chung CY, Sharma A, Robertson GP. Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol 2010; 176: 2948-2957.
73. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF et al. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002; 21: 4212-4219. (Pubitemid 34753827)
74. Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN et al. GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res 2010; 16: 3851-3859.
75. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A et al. RNA interference targeting transforming growth factor-beta enhances NKG2Dmediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004; 64: 7596-7603. (Pubitemid 39372105)
76. Senapati S, Rachagani S, Chaudhary K, Johansson SL, Singh RK, Batra SK. Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene 2010; 29: 1293-1302.
77. Ostroukhova M, Qi Z, Oriss TB, Dixon-McCarthy B, Ray P, Ray A. Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membranebound TGF-beta. J Clin Invest 2006; 116: 996-1004.
78. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-1547. (Pubitemid 28233009)
79. Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR et al. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostatespecific antigen improves prostate cancer diagnosis. Clin Cancer Res 2006; 12: 89-96. (Pubitemid 43166181)
80. Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, Jung K et al. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer 2003; 88: 1101-1104. (Pubitemid 36560783)
81. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 2003; 100: 3410-3415. (Pubitemid 36356597)
82. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25-29. (Pubitemid 43041217)
83. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51: 1202-1216. (Pubitemid 46436310)
84. Taniguchi S, Taoka R, Inui M, Sugimoto M, Kakehi Y. Influence of inflammation and aging on macrophage inhibitory cytokine-1 gene expression in rat ventral prostate. Urology 2009; 73: 410-414.
85. Taoka R, Tsukuda F, Ishikawa M, Haba R, Kakehi Y. Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia. J Urol 2004; 171 (6 Pt 1): 2330-2335. (Pubitemid 38625464)
86. Brown DA, Lindmark F, Stattin P, Balter K, Adami HO, Zheng SL et al. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res 2009; 15: 6658-6664.
87. Noorali S, Kurita T, Woolcock B, de Algara TR, Lo M, Paralkar V et al. Dynamics of expression of growth differentiation factor 15 in normal and PIN development in the mouse. Differentiation 2007; 75: 325-336. (Pubitemid 46434952)
88. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 1998; 78: i-xv.
89. Cheng I, Krumroy LM, Plummer SJ, Casey G, Witte JS. MIC1 and IL1RN genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007; 16: 1309-1311. (Pubitemid 46984978)
90. Wang X, Chrysovergis K, Bienstock RJ, Shim M, Eling TE. The H6D variant of NAG-1/GDF15 inhibits prostate xenograft growth in vivo. Prostate 2011; e-pub ahead of print 1 August 2011.
91. Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castrationresistant prostate cancer. Annals Oncol 2010; 21: 2135-2144.
92. Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N et al. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res 2009; 69: 7696-7703.
93. Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH et al. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 2007; 13: 5825-5833. (Pubitemid 47583907)
94. Chen S-J, Karan D, Johansson SL, Lin F-F, Zeckser J, Singh AP et al. Prostatederived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate 2007; 67: 557-571. (Pubitemid 46536948)
95. Karan D, Chen S-J, Johansson SL, Singh AP, Paralkar VM, Lin M-F et al. Dysregulated expression of MIC-1/PDF in human prostate tumor cells. Biochem and Biophys Res Commun 2003; 305: 598-604. (Pubitemid 36579273)
96. Cheng JC, Chang HM, Leung PC. Wild-Type p53 attenuates cancer cell motility by inducing growth differentiation factor-15 expression. Endocrinology 2011; 152: 2987-2995.
97. Vanhara P, Lincova E, Kozubik A, Jurdic P, Soucek K, Smarda J. Growth/ differentiation factor-15 inhibits differentiation into osteoclasts-a novel factor involved in control of osteoclast differentiation. Differentiation 2009; 78: 213-222.
98. Lambert JR, Kelly JA, Shim M, Huffer WE, Nordeen SK, Baek SJ et al. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol 2006; 208: 566-574. (Pubitemid 44141881)
99. Wynne S, Djakiew D. NSAID inhibition of prostate cancer cell migration is mediated by Nag-1 induction via the p38 MAPK-p75(NTR) pathway. Mol Cancer Res 2010; 8: 1656-1664.
100. Massague J. TGFbeta in Cancer. Cell 2008; 134: 215-230.
101. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 2010; 16: 5842-5851.
102. Park YJ, Lee H, Lee JH. Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells. BMB Rep 43: 91-96.
103. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003; 9: 2642-2650. (Pubitemid 36842108)
104. Kim IY, Park SY, Kang Y, Thapa D, Choi HG, Kim JA. Role of nonsteroidal anti-inflammatory drug-activated gene-1 in docetaxel-induced cell death of human colorectal cancer cells with different p53 status. Arch Pharm Res 2011; 34: 323-330.
105. Shnaper S, Desbaillets I, Brown DA, Murat A, Migliavacca E, Schluep M et al. Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer 2009; 125: 2624-2630.
106. Lin TY, Chang JT, Wang HM, Chan SH, Chiu CC, Lin CY et al. Proteomics of the radioresistant phenotype in head-and-neck cancer: Gp96 as a novel prediction marker and sensitizing target for radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78: 246-256.
107. Skipworth RJ, Deans DA, Tan BH, Sangster K, Paterson-Brown S, Brown DA et al. Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer. Br J Cancer 2010; 102: 665-672.
108. Staff AC, Bock AJ, Becker C, Kempf T, Wollert KC, Davidson B. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol 2010; 118: 237-243.
109. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004; 10: 2386-2392. (Pubitemid 38445697)
110. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006; 12: 442-446. (Pubitemid 43166133)
111. Selander KS, Brown DA, Sequeiros GB, Hunter M, Desmond R, Parpala T et al. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev 2007; 16: 532-537. (Pubitemid 46548657)